While growth metrics for Infosys was skewed to a single vertical and it is struggling to get a handle on costs, TCS has been able to manage growth and keep cost inflation under control.
The rap from both the US and UK drug regulators, including the latest one from the latter, has hit the scrip.
Even as rising crude oil prices, trade war fears and a sliding rupee cast a shadow on market sentiment, Nischal Maheshwari, chief executive officer for institutional equities and advisory at Centrum Broking, tells Puneet Wadhwa that in the next one year, the outcome of the 2019 general election is a bigger challenge for the market.
Sector analysts opined that the northern, central and eastern markets were particularly hit
Increased price control over branded generic medicines has affected its profitability
The combined market capitalisation of the 21 listed PSU banks declined by about Rs 76,000 crore to Rs 425,800 crore during the month.
Overnight, the Wall Street closed on a flatter note.
Analysts are divided on the deal valuations. Some say Torrent could have bargained harder, as Sanofi, among others, passed it over.
Cipla, though late in changing its strategy for international markets, has in recent years taken an inorganic route for expansion.
Markets ended weak tracking the expiry of April derivative contracts.
Reports have suggested Rs 400-650 as the possible IPO price
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
Reserve requirements, mandatory investment in G-secs under Companies Act may slow lending for HNI investment in IPOs.
TCS had earlier this week announced that it too would be hiring less number of freshers.
Volatility might continue as the Chinese market is expected to open sharply lower, following a long break
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
The industry feels that prices of active pharmaceutical ingredients (APIs) can go up in the range of 5-15 per cent.
In Q3, E&P business accounted for just 1.5% of gross revenue
The finance ministry is resisting pressure from other departments to cap foreign ownership of domestic drugmakers, fearing such a move would discourage potential investors, a senior ministry source said.
Annualised staff attrition rate at Infosys rose to a record 20.1 per cent in the September quarter.
Experts say investors should be careful, as even a 50-100 bps cut in rates will not help such companies if their business is not doing well. Check what is the problem and consider
Markets end in green with auto, banks on a steady climb.
Sensex witnessed the biggest single day gain since May 2009 in absolute terms.
Many people struggle to claim or liquidate investments and insurance policies due to procedural issues.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances